TreatmentXisuicensedas an effectivetreatmentforunqcancer.The pharmaceuticaucompanythat markets
treatmentXbeuievesthasabeneficiaueffectonauauityofufe.Beforeembarkingonafullrscalerandomised
controlledtriauthecompanytesteditshypothesis in an open study restricted justto patients prescribed
treatment√ó.Each patientcompleted avalidated qualityzof-ufe scale at thestartof treatmemtandthen12
monthsuater.Thescaleqives inteqervalues betwveen0and50;scores above30areconsidered to be
desirable.
Whichoneofthefouowina methodsisbest for presentinatheresutsfromthis studv?
Averagechangein scale scores, with its95oconfidence uimits
Changeintheproportionofpatientswithscoresabovethedesired cut-offeveu.withits95
confidenceuimitsy
Chizsauaretestandp-valueforpre-andpost-studyproportionsabovethedesired cut-offueveL
Meanscores atthestartandendofthetreatment period. withtheir standarddeviations
Unpairedt-test statistic and p-valueonly
@1MINENDOCRINE
